Friedreich’s ataxia therapeutic / Agios Pharma - LARVOL DELTA

Agios reports first quarter 2020 financial results and provides update on business operations and Covid-19 response (GlobeNewswire) - "Agios conducted a prioritization exercise and made the decision to pause certain research programs, including its program in Friedreich's Ataxia....In order to conserve cash while supporting the execution of critical business objectives during this period of uncertainty, Agios has made decisions to...delay select research programs, including the Friedreich’s Ataxia program..."

Clinical • Friedreich ataxia • Genetic Disorders